Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.

Human prostate cancer is initially dependent on androgens for growth, and androgen-dependent cells undergo apoptosis after castration. However, a subset of androgen-responsive cells survives and eventually proliferates in the absence of testicular androgen. The high levels of androgen receptor in both androgen-dependent and recurrent tumors led us to investigate androgen regulation of cell cycle proteins in human prostate cancer using the CWR22 xenograft. Cellular proliferation decreased dramatically in CWR22 tumors after castration. Testosterone propionate (TP) treatment of castrated mice restored cellular proliferation after 24-48 hours. Growth of CWR22 tumors in the absence of testicular androgen recurred several months after castration. CDK1 and CDK2, and cyclin A and cyclin B1 messenger RNAs were decreased 6 days after castration, increased 6-12 hours after TP treatment, and were expressed at high levels in recurrent CWR22 tumors. Coimmunoprecipitated cyclin B1/CDK1 and cyclin D1/CDK4 protein complexes decreased after castration and increased after TP treatment of castrated mice. In addition, CDK1 and CDK2 kinase activities were upregulated by androgen in parallel with hyperphosphorylation of retinoblastoma (Rb) protein. Despite the absence of testicular androgen in recurrent CWR22, the levels of these androgen-regulated cyclin/ CDK protein complexes and hyperphosphorylation of Rb were equal to or greater than in tumors from intact mice. The results indicate that androgen receptor regulates cellular proliferation by control of CDK and cyclins at the transcriptional level and by post-translational modifications that influence cell cycle protein activity.

[1]  P. Gumerlock,et al.  Human androgen receptor expression in prostate cancer following androgen ablation. , 1997, European urology.

[2]  D. Livingston,et al.  Specific enzymatic dephosphorylation of the retinoblastoma protein , 1993, Molecular and cellular biology.

[3]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[4]  Paul Nurse,et al.  Ordering S phase and M phase in the cell cycle , 1994, Cell.

[5]  W. Cavenee,et al.  D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. , 1999, Cancer research.

[6]  J. Harbour,et al.  Rb function in cell-cycle regulation and apoptosis , 2000, Nature Cell Biology.

[7]  M. Rosner,et al.  Role of cyclins in neuronal differentiation of immortalized hippocampal cells , 1997, Molecular and cellular biology.

[8]  C. Conti,et al.  Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1 , 1998, Oncogene.

[9]  W. Strauss.  Preparation of Genomic DNA from Mammalian Tissue , 1998, Current protocols in molecular biology.

[10]  P. Dirks,et al.  Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. , 1996, Critical reviews in biochemistry and molecular biology.

[11]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[12]  C S Song,et al.  Regulation of androgen action. , 1999, Vitamins and hormones.

[13]  M. Rosner,et al.  Cyclin D1 is required for S phase traversal in bovine tracheal myocytes. , 1997, The American journal of physiology.

[14]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[15]  L. Hartwell,et al.  Checkpoints: controls that ensure the order of cell cycle events. , 1989, Science.

[16]  A. Robles,et al.  Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[18]  J. Isaacs.  Role of androgens in prostatic cancer. , 1994, Vitamins and hormones.

[19]  M. M. Sanders,et al.  Ten years after: reclassification of steroid-responsive genes. , 1996, Molecular endocrinology.

[20]  P. J. Welch,et al.  The retinoblastoma tumor suppressor protein. , 1994, Advances in cancer research.

[21]  F. S. French,et al.  Androgen receptor defects : Historical, clinical, and molecular perspectives , 1995 .

[22]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[23]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[24]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[25]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[26]  M. Danielsen,et al.  Differential Regulation of Androgen and Glucocorticoid Receptors by Retinoblastoma Protein* , 1998, The Journal of Biological Chemistry.

[27]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[28]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[29]  W. Nelson,et al.  Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. , 1995, Endocrinology.

[30]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[31]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[32]  C. Cordon-Cardo,et al.  Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.

[33]  M. Gossen,et al.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. , 1994, Molecular and cellular biology.

[34]  M. Tsai,et al.  Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. , 1997, Cancer research.

[35]  S. Mittnacht,et al.  pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F , 1998, Oncogene.

[36]  W. Cavenee,et al.  Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[37]  S. Yeh,et al.  Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. , 1998, Biochemical and biophysical research communications.

[38]  J. Tilly,et al.  Microscale autoradiographic method for the qualitative and quantitative analysis of apoptotic DNA fragmentation , 1993, Journal of cellular physiology.